Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 600.18% and ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

The most recent trading session ended with Eli Lilly (LLY) standing at $909.32, reflecting a -1.65% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.4%.

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...